SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Chloramphenicol sodium succinate <TRADE NAME> <STRENGTH> Powders for solutions for injections or infusions

<REGARDING THE APPROVAL>

1. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains <STRENGTH> of chloramphenicol sodium succinate (equivalent to <STRENGTH> of chloramphenicol).

For the full list of excipients, see section 6.1.

<REGARDING THE APPROVAL>

1. PHARMACEUTICAL FORM

Powder for solution for injection. <REGARDING THE APPROVAL>

1. CLINICAL PARTICULARS
	1. Therapeutic indications

Chloramphenicol is indicated for typhoid, meningitis caused by H. influenzae and other serious infections caused by bacteria susceptible to chloramphenicol.

Chloramphenicol should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of the infections listed above, or when these alternative antibacterial agents have failed to demonstrate efficacy.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

It is also indicated wherever chloramphenicol is deemed the antibiotic of choice and oral administration is not possible, or where higher than usual blood concentrations are required.

* 1. Posology and method of administration

**Posology**

The dose administered and the concentration used is dependent on the severity of the infection. The recommended standard dosage is as follows:

**Adults**

The equivalent of 1g of chloramphenicol every 6-8 hours.

**Children**

The equivalent of 50mg/kg chloramphenicol according to body weight, daily in divided doses every 6 hours (this dose should not be exceeded). The patient should be carefully observed for signs of toxicity.

**Neonates and Premature Infants**

A total of 25 mg/kg/day in 4 equal doses at 6-hour intervals usually produces and maintains concentrations in blood and tissues adequate to control most infections for which the drug is indicated.

**Elderly**

The usual adult dosage should be given subject to normal hepatic and renal function.

Only 10% or lower concentrations to be used. The injection should be reconstituted in water for injections, sodium chloride injection or dextrose injection 5%. The product for intramuscular injection should be reconstituted only in water for injections; the osmolarity of sodium chloride injection or dextrose injection 5% may cause pain at the site of injection.

**Dosage in special clinical conditions**

In exceptional cases, such as patients with septicaemia or meningitis, dosage schedule up to 100 mg/kg/day may be prescribed. However, these high doses should be decreased as soon as clinically indicated. To prevent relapses treatment should be continued after the temperature has returned to normal for 4 days in rickettsial diseases and for 8-10 days in typhoid fever.

**Method of administration**

To be given by intravenous or intramuscular injection. In order to ensure rapid attainment of high blood levels, Chloramphenicol Injection is best administered by intravenous injection. Where this is not possible, intramuscular administration may be used, although absorption may be slow and unpredictable. The use of the intramuscular route should be restricted to those patients where parenteral administration is considered most appropriate but intravenous use is impossible or impractical. Intravenous administration should be as a 10% (100 mg/mL) solution to be injected over at least a one-minute interval, or in a larger volume of fluid, by slow intravenous infusion after reconstitution (see section 6.6). The same 10% (100 mg/mL) solution can also be administered intra-muscularly, if necessary. Since the recommended dose for neonates and premature infants is 25 mg/kg daily, divided in multiple doses, it might be difficult to achieve such a dose with 100 mg/ml (10%) concentration in case of a small infant. In such cases, a solution of lower concentration may be used.

* 1. Contraindications

Chloramphenicol is contraindicated in patients with a previous history of sensitivity and/or toxic reaction to chloramphenicol.

* 1. Special warnings and precautions for use

Chloramphenicol is to be administered only under the direction of a medical practitioner. It should be reserved for serious infections caused by organisms susceptible to its antimicrobial effects when less toxic antibiotics are ineffective or contraindicated. However, chloramphenicol may be chosen to initiate antibiotic therapy based on the clinical impression. In vitro sensitivity tests should be performed concurrently so that the drug may be discontinued as soon as possible ia less toxic antibiotic is indicated by the results of such tests. The decision to continue use of chloramphenicol, rather than another antibiotic when both are suggested by in vitro studies to be effective against a specific pathogen, should be based upon severity of the infection, susceptibility of the pathogen to the various antimicrobial drugs, and the efficacy of the various drugs in the infection.

Chloramphenicol should not be used for trivial infections due to the possibility of severe blood dyscrasias, which may prove fatal.

Bone marrow depression and blood disorders

Serious and fatal blood dyscrasias (aplastic anaemia, hypoplastic anaemia, thrombocytopenia, granulocytopenia and bone marrow depression) are known to occur after the administration of chloramphenicol. (See section 4.8). In addition, there have been reports of aplastic anaemia attributed to chloramphenicol, which later resulted in leukaemia. Blood dyscrasias have occurred after both short-term and prolonged therapy with this drug. Chloramphenicol must not be used in the treatment of any infection for which a less toxic antibiotic is available (see section 4.1).

Patient monitoring

Because of its toxic nature it is important to monitor serum levels of this antibiotic particularly in new-born and premature infants, in the elderly, in patients with renal or hepatic disease and in those receiving other drugs with which chloramphenicol may interact (see section 4.5).

It is essential that adequate haematologic functions be closely monitored during treatment with chloramphenicol. While haematologic determinations may detect early peripheral haematologic changes, such as leucopoenia, reticulocytopenia, or granulocytopenia, before they become irreversible, such determinations cannot be relied on to detect bone marrow depression prior to the development of aplastic anaemia.

It is desirable that patients be hospitalized during therapy, so that appropriate laboratory determinations and clinical observations can be made.

Baseline haematologic determinations should be made and determinations repeated approximately every two days during therapy. The drug should be discontinued upon appearance of reticulocytopenialeucopoenia, thrombocytopenia, anaemia, or any other haematologic findings attributable to chloramphenicol. However, such determinations do not exclude the possible later appearance of the irreversible type of bone marrow depression.

Repeated courses of the drug should be avoided if at all possible. Treatment should not be continued longer than required to produce a cure with little or no risk of relapse of the disease. Concurrent therapy with other drugs that may cause bone marrow depression should be avoided.

Hepatic or Renal Impairment

Excessive chloramphenicol serum levels may result from administration of the recommended dose to patients with impaired liver or kidney function, including that due to immature metabolic processes in the infant. Dosage should be adjusted accordingly or, preferably, the serum concentration should be determined at appropriate intervals. (See section 4.2).

Grey syndrome in infants and neonates

Precaution should be used in therapy of premature and full-term neonates to avoid “Grey-Syndrome” toxicity. Serum drug levels should be carefully monitored during therapy of the neonate (newborn infant). Toxic reactions, including fatalities, have occurred in premature infants and neonates. The signs and symptoms associated with these reactions have been referred to as the “Grey Syndrome”. Although “Grey Syndrome” has been reported in neonates born to mothers after having received chloramphenicol during labour, in most cases therapy with chloramphenicol has been instituted within the first 48 hours of life. The following summarizes the clinical and laboratory determinations that have been made on these patients. Symptoms first appeared after 3 to 4 days of continued treatment with high doses of chloramphenicol. The symptoms appeared in the following order: abdominal distension with or without emesis, progressive pallid cyanosis, vasomotor collapse, frequently accompanied by irregular respiration, death within a few hours of onset of these symptoms.

The progression of symptoms from onset to death was accelerated with higher dose schedules. Serum drug levels revealed unusually high concentrations of chloramphenicol (over 90mcg/mL after repeated doses).

Termination of therapy upon early evidence of the associated symptomatology frequently reversed the process with complete recovery following.

General

Chloramphenicol must not be used in the treatment of trivial infections or where it is not indicated, as in colds, viral influenza, infections of the throat or as a prophylactic agent to prevent bacterial infections.

Superinfections

The use of chloramphenicol, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. If infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken.

Clostridium difficile associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents, including chloramphenicol, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD.

Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

Effects on immunity

Chloramphenicol may also impede the development of immunity and should therefore not be given during active immunisation.

**Excipient information**

<REGARDING THE APPROVAL>

* 1. Interaction with other medicinal products and other forms of interaction

Chloramphenicol has been shown to interact with, and enhance the effects of coumarin anticoagulants, some hypoglycaemic agents (e.g. tolbutamide) and phenytoin. When given concurrently, a dose reduction of these agents may be necessary.

Plasma concentrations of chloramphenicol may be reduced with concomitant usage of phenobarbital and rifampicin.

* 1. Fertility, pregnancy and lactation

**Pregnancy**

The use of chloramphenicol is contraindicated**.**

**Breast-feeding**

The use of chloramphenicol is contraindicated.

* 1. Effects on ability to drive and use machines

No or negligible influence.

* 1. Undesirable effects

Tabulated summary of adverse reactions

The adverse reactions are grouped according to their system organ classes and the frequencies ranked according to the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); frequency not known (cannot be estimated from the available data).

**Infections and infestations:**

Frequency not known: Fungal superinfection

**Blood and lymphatic system disorders**:

Very Rare: Aplastic anaemia.

Frequency not known: Agranulocytosis, Bone marrow failure, Pancytopenia, Thrombocytopenic, purpura

**Psychiatric disorders:**

Frequency not known: Depression

**Nervous system disorders**:

Frequency not known: Peripheral neuritis, headache.

**Eye disorders:**

Frequency not known: Optic neuritis, Transient blindness, Blurred vision

**Cardiac disorders:**

Frequency not known: Neonatal Grey syndrome.

**Gastro-intestinal disorders**:

Frequency not known: Vomiting, Diarrhoea, Nausea, Dry mouth.

**Skin and subcutaneous tissue disorders**:

Frequency not known: Urticaria.

Bone marrow depression and blood disorders

Chloramphenicol may cause severe bone marrow depression which may lead to serious and potentially fatal blood dyscrasias, such as agranulocytosis, thrombocytopenic purpura or aplastic anaemia (see section 4.4)

Paediatric population

Grey syndrome is a serious adverse effect that has been reported in neonates and infants following the intravenous administration of chloramphenicol (see section 4.4)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Health Product Vigilance Center; HPVC.

* 1. Overdose

Levels exceeding 25mcg/ml are frequently considered toxic.

Symptoms

Chloramphenicol toxicity can be evidenced by serious haemopoietic effects such as aplastic anaemia, thrombocytopenia, leucopoenia, as well as increasing serum iron levels, nausea, vomiting and diarrhoea.

Management

In the case of serious overdosage, charcoal haemoperfusion may be effective in removing chloramphenicol from plasma.

Exchange transfusion is of questionable value following massive overdosage, especially in neonates and infants.

1. PHARMACOLOGICAL PROPERTIES
	1. Pharmacodynamic properties

Pharmacotherapeutic group: Antibacterials for systemic use. Amphenicols. ATC code: J01BA01.

Chloramphenicol is active against many gram-positive and gram-negative organisms, Spirillae and Rickettsia. It acts by interfering with bacterial protein synthesis.

* 1. Pharmacokinetic properties

**Absorption**

After intravenous administration steady state peak concentrations were reached on average 18.0 minutes after cessation of the infusion.

**Distribution**

Chloramphenicol is widely distributed in body tissues and fluids and enters the cerebrospinal fluid.

**Biotransformation**

After administration chloramphenicol is rapidly released from chloramphenicol sodium succinate. Chloramphenicol sodium succinate, free chloramphenicol and metabolites are excreted in the urine.

**Elimination**

After intravenous administration of chloramphenicol succinate every 6 hours, the elimination half-lives were 4.03 hours for chloramphenicol and 2.65 hours for chloramphenicol succinate.

**Paediatric population**

In infants and children aged 3 days to 16 years the apparent half-life was extremely variable ranging from 1.7 to 12.0 hours.

* 1. Preclinical safety data

Not applicable.

1. PHARMACEUTICAL PARTICULARS
	1. List of excipients

<REGARDING THE APPROVAL>

* 1. Incompatibilities

Not applicable.

* 1. Shelf life

<REGARDING THE APPROVAL>

* 1. Special precautions for storage

<REGARDING THE APPROVAL>

* 1. Nature and contents of container

<REGARDING THE APPROVAL>

* 1. Special precautions for disposal

Chloramphenicol should be administered intravenously as a 10% (100 mg/ml) solution or lower, that can be prepared by diluting the lyophilized powder in the vial with 9.2 ml of diluent (see table below). The resulting solution can be administered as an intravenous bolus, intravenous infusion or intramuscular injection. The use of the intramuscular route should be, however, restricted only to those patients where intravenous access is unavailable. The solution can be reconstituted with the following diluents:

- Water for injections

- 0.9% sodium chloride

- 5% dextrose

|  |  |  |  |
| --- | --- | --- | --- |
| **1 vial containing 1.377g of chloramphenicol sodium succinate (equivalent to 1.0 g of laevorotatory chloramphenicol** | **Route of administration** | **Amount of diluent to be added (ml)** | **Resulting concentration in mg/ml (%)** |
|  | Intravenous bolus (1 minute)Slow intravenous infusionIntramuscular injection | 9.2 ml | 100 mg/ml (10%) |

\*Includes 0.8 ml water from gaseous phase in vial

<REGARDING THE APPROVAL>

1. MARKETING AUTHORISATION HOLDER

<REGARDING THE APPROVAL>

1. MARKETING AUTHORISATION NUMBER(S)

<REGARDING THE APPROVAL>

1. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

<REGARDING THE APPROVAL>

1. DATE OF REVISION OF THE TEXT1

<REGARDING THE APPROVAL>